Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
Seres Therapeutics, Inc. (MCRB)
Last seres therapeutics, inc. earnings: 11/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.serestherapeutics.com
Company Research
Source: Business Wire
Continued market adoption of VOWST® with approximately 1,411 patient enrollment forms received, approximately 1,083 new patient starts, and net sales of $10.1 million during Q1 2024, and accelerated net sales in March and AprilSER-155 Phase 1b placebo-controlled Cohort 2 clinical readout expected end of Q3 2024Further microbiome therapeutic candidates have potential to expand product franchise into additional medically vulnerable patient populationsConference call at 8:30 a.m. ET today CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2024 financial results and provided business updates."With a broad indication and compelling clinical profile to prevent the recurrence of Clostridioides difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI (rCDI), VOWST enables healthcare providers to fundamentally transform how they treat this life-threatening disease.
Show less
Read more
Impact Snapshot
Event Time:
MCRB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MCRB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MCRB alerts
High impacting Seres Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MCRB
News
- Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Seres Therapeutics, Inc. (NASDAQ: MCRB) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $5.00 to $4.00. They now have an "outperform" rating on the stock.MarketBeat
- Seres Therapeutics, Inc. (NASDAQ: MCRB) had its price target lowered by analysts at Chardan Capital from $8.00 to $6.00. They now have a "buy" rating on the stock.MarketBeat
- Seres Therapeutics First Quarter 2024 Earnings: US$0.28 loss per share (vs US$0.56 loss in 1Q 2023) [Yahoo! Finance]Yahoo! Finance
- World $2.5 Bn Human Microbiome Market Trends, Forecasts and Competitive Analysis 2018-2023 and 2024-2030 [Yahoo! Finance]Yahoo! Finance
MCRB
Earnings
- 5/8/24 - Beat
MCRB
Sec Filings
- 5/17/24 - Form 4
- 5/17/24 - Form 4
- 5/17/24 - Form 4
- MCRB's page on the SEC website